Hematologic toxicity in 20 patients receiving a 75-cGy whole-body dose
| . | Absolute neutrophil count . | Platelets . | Hemoglobin . |
|---|---|---|---|
| Time to nadir (days) | |||
| Median | 43 | 35 | 41 |
| 95% confidence interval | 41-55 | 33-37 | 33-48 |
| Range | 22-106 | 29-45 | 6-78 |
| Time to recovery to baseline (days) | |||
| Median | 64 | 51 | 50 |
| 95% confidence interval | 58-84 | 48-55 | 37-62 |
| Range | 29-159 | 37-405 | 9-9 |
| Maximum toxicity | |||
| Grade III | 35% | 20% | 5% |
| Grade IV | 20% | 20% | 5% |
| Median duration of grade IV (days) | 11.5 | 19 | 2 |
| Range | 10-22 | 2-85+ | 2-2 |
| Supportive care | |||
| Any supportive care | 4 (20%) | ||
| G-CSF | 2 (10%) | ||
| GM-CSF | 0 (0%) | ||
| Erythropoietin | 0 (0%) | ||
| Platelet transfusion | 3 (15%) | ||
| RBC transfusion | 3 (15%) | ||
| . | Absolute neutrophil count . | Platelets . | Hemoglobin . |
|---|---|---|---|
| Time to nadir (days) | |||
| Median | 43 | 35 | 41 |
| 95% confidence interval | 41-55 | 33-37 | 33-48 |
| Range | 22-106 | 29-45 | 6-78 |
| Time to recovery to baseline (days) | |||
| Median | 64 | 51 | 50 |
| 95% confidence interval | 58-84 | 48-55 | 37-62 |
| Range | 29-159 | 37-405 | 9-9 |
| Maximum toxicity | |||
| Grade III | 35% | 20% | 5% |
| Grade IV | 20% | 20% | 5% |
| Median duration of grade IV (days) | 11.5 | 19 | 2 |
| Range | 10-22 | 2-85+ | 2-2 |
| Supportive care | |||
| Any supportive care | 4 (20%) | ||
| G-CSF | 2 (10%) | ||
| GM-CSF | 0 (0%) | ||
| Erythropoietin | 0 (0%) | ||
| Platelet transfusion | 3 (15%) | ||
| RBC transfusion | 3 (15%) | ||
G-CSF indicates granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; RBC, red blood cell.